Phase I clinical study of peptide vaccine using novel tumor-associated antigen TTK against advanced esophageal carcinoma
Phase 1
- Conditions
- Advanced esophageal cancer refractory to standard therapeutic modality
- Registration Number
- JPRN-UMIN000001014
- Lead Sponsor
- niversity of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
Pregnancy Uncontrolled infection Uncontrolled brain metastasis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Antitumor immune responses